{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:01:38Z","timestamp":1775001698645,"version":"3.50.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Recurrent and metastatic pheochromocytoma (PCC) are rare advanced endocrine neoplasms with limited treatment options. Insight into the pathogenic molecular alterations in patients with advanced PCC can provide therapeutic options for precisely targeting dysregulated pathways.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We report the discovery and characterization of a novel BRAF-containing fusion transcript and its downstream molecular alterations in a patient with recurrent PCC with peritoneal seeding (pheochromocytomatosis).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed the medical record of a patient with pheochromocytomatosis. A comprehensive pan-cancer molecular profiling using next-generation sequencing (NGS) as well as confirmatory real-time-quantitative PCR were performed on surgical specimens. BRAF rearrangement and downstream molecular changes were assayed using fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. Western blot was used to assess the in vitro activation of the mitogen-activated protein kinase (MAPK) signaling pathway and the EMT markers in transfected HEK-293 cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The NGS analysis of a specimen from a 72-year-old female patient with pheochromocytomatosis showed an in-frame fusion of exon 3 of Glucocorticoid Induced 1 (GLCCI1) to exon 9 of BRAF. The upstream auto-inhibitory domain of BRAF was excluded from the GLCCI1-BRAF fusion; however, the downstream BRAF kinase domain was intact. A BRAF rearrangement was confirmed via a BRAF-specific break-apart FISH assay. Four separate tumor foci harbored GLCCI1-BRAF fusion. IHC demonstrated increased phosphorylated MEK. HEK-293 cells transfected with the GLCCI1-BRAF fusion demonstrated increased phosphorylated MEK as well as higher expression of EMT markers SNAI1 and ZEB1 in vitro.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We demonstrate a novel pathogenic gene fusion of GLCCI1 with the oncogenic kinase domain of BRAF, resulting in an activation of the MAPK signaling pathway and EMT markers. Thus, this patient may benefit from clinically available MEK and\/or BRAF inhibitors when systemic therapy is indicated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary statement<\/jats:title>\n                  <jats:p>This report is the first of GLCCI1 fused to BRAF in a human neoplasm and only the second BRAF-containing fusion transcript in PCC. Detailed molecular characterization of PCC can be a valuable tool in managing patients with recurrent PCC and pheochromocytomatosis that represents a significant clinical challenge.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1530\/eje-21-0797","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:44:42Z","timestamp":1654605882000},"page":"185-196","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":6,"title":["Novel GLCCI1-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-198X","authenticated-orcid":false,"given":"Benjamin L","family":"Green","sequence":"first","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-5959","authenticated-orcid":false,"given":"Robert R C","family":"Grant","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher T","family":"Richie","sequence":"additional","affiliation":[{"name":"Genetic Engineering and Viral Vector Core, Intramural Research Program, Biomedical Research Center, National Institute on Drug Abuse , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishwanath","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelly","family":"Sampaio De Melo","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic G","family":"Barr","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita K","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7348-7804","authenticated-orcid":false,"given":"Naris","family":"Nilubol","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, National Cancer Institute, National Institutes of Health , Bethesda, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"2023010809170179600_bib1","first-page":"101","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nature Reviews: Endocrinology"},{"key":"2023010809170179600_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"Turchini","year":"2018","journal-title":"Histopathology"},{"key":"2023010809170179600_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"2023010809170179600_bib4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1677\/erc.1.00829","article-title":"Malignant pheochromocytoma: current status and initiatives for future progress","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocrine-Related Cancer"},{"key":"2023010809170179600_bib6","doi-asserted-by":"crossref","first-page":"E2681","DOI":"10.1210\/jc.2014-1975","article-title":"Peritoneal implantation of pheochromocytoma following tumor capsule rupture during surgery","volume":"99","author":"Rafat","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/000313481007600810","article-title":"Pheochromocytomatosis: a risk after pheochromocytoma surgery","volume":"76","author":"Robledo","year":"2010","journal-title":"American Surgeon"},{"key":"2023010809170179600_bib8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1067\/msy.2001.118373","article-title":"Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy","volume":"130","author":"Li","year":"2001","journal-title":"Surgery"},{"key":"2023010809170179600_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"2023010809170179600_bib10","doi-asserted-by":"crossref","first-page":"33030","DOI":"10.18632\/oncotarget.26050","article-title":"Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response","volume":"9","author":"Nilubol","year":"2018","journal-title":"Oncotarget"},{"key":"2023010809170179600_bib11","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","article-title":"CDK4 amplification reduces sensitivity to CDK4\/6 inhibition in fusion-positive rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"2023010809170179600_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/ijc.29825","article-title":"The distribution of BRAF gene fusions in solid tumors and response to targeted therapy","volume":"138","author":"Ross","year":"2016","journal-title":"International Journal of Cancer"},{"key":"2023010809170179600_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1634\/theoncologist.2012-0410","article-title":"Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas","volume":"18","author":"Lowery","year":"2013","journal-title":"Oncologist"},{"key":"2023010809170179600_bib14","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","article-title":"Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review","volume":"51","author":"Berends","year":"2018","journal-title":"European Journal of Internal Medicine"},{"key":"2023010809170179600_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocrine Reviews"},{"key":"2023010809170179600_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40618-020-01344-z","article-title":"Management and outcome of metastatic pheochromocytomas\/paragangliomas: an overview","volume":"44","author":"De Filpo","year":"2021","journal-title":"Journal of Endocrinological Investigation"},{"key":"2023010809170179600_bib18","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.soc.2006.05.009","article-title":"Malignant pheochromocytoma","volume":"15","author":"Zarnegar","year":"2006","journal-title":"Surgical Oncology Clinics of North America"},{"key":"2023010809170179600_bib19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"2023010809170179600_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Annals of Surgery"},{"key":"2023010809170179600_bib21","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocrine-Related Cancer"},{"key":"2023010809170179600_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/a-0851-3275","article-title":"Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review","volume":"51","author":"Mei","year":"2019","journal-title":"Hormone and Metabolic Research"},{"key":"2023010809170179600_bib24","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocrine-Related Cancer"},{"key":"2023010809170179600_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"American Journal of Surgical Pathology"},{"key":"2023010809170179600_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/a-0715-1888","article-title":"Metastatic phaeochromocytoma: spinning towards more promising treatment options","volume":"127","author":"Nolting","year":"2019","journal-title":"Experimental and Clinical Endocrinology and Diabetes"},{"key":"2023010809170179600_bib28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"Nolting","year":"2019","journal-title":"Cancers"},{"key":"2023010809170179600_bib29","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib30","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic Sdhb and sporadic pheochromocytoma\/paraganglioma: an National Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocrine Practice"},{"key":"2023010809170179600_bib31","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn","year":"2006","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2023010809170179600_bib32","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nature Communications"},{"key":"2023010809170179600_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3390\/cancers11040436","article-title":"Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies","volume":"11","author":"Pang","year":"2019","journal-title":"Cancers"},{"key":"2023010809170179600_bib34","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.2147\/OTT.S219056","article-title":"Therapies targeting the signal pathways of pheochromocytoma and paraganglioma","volume":"12","author":"Liu","year":"2019","journal-title":"OncoTargets and Therapy"},{"key":"2023010809170179600_bib35","doi-asserted-by":"crossref","first-page":"14169","DOI":"10.1038\/s41598-020-71040-8","article-title":"Human transcription factor and protein kinase gene fusions in human cancer","volume":"10","author":"Salokas","year":"2020","journal-title":"Scientific Reports"},{"key":"2023010809170179600_bib36","doi-asserted-by":"crossref","first-page":"227.e3","DOI":"10.1016\/j.celrep.2018.03.050","article-title":"Driver fusions and their implications in the development and treatment of human cancers","volume":"23","author":"Gao","year":"2018","journal-title":"Cell Reports"},{"key":"2023010809170179600_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nature Genetics"},{"key":"2023010809170179600_bib38","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm.2166","article-title":"Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma","volume":"16","author":"Palanisamy","year":"2010","journal-title":"Nature Medicine"},{"key":"2023010809170179600_bib39","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"key":"2023010809170179600_bib40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2023010809170179600_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"Lavoie","year":"2015","journal-title":"Nature Reviews: Molecular Cell Biology"},{"key":"2023010809170179600_bib42","first-page":"676","article-title":"New perspectives for targeting RAF kinase in human cancer","volume":"17","author":"Karoulia","year":"2017","journal-title":"Nature Reviews: Cancer"},{"key":"2023010809170179600_bib43","doi-asserted-by":"crossref","first-page":"138573","DOI":"10.1155\/2015\/138573","article-title":"Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis","volume":"2015","author":"Luchetti","year":"2015","journal-title":"International Journal of Endocrinology"},{"key":"2023010809170179600_bib44","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/cancers11091262","article-title":"BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors","volume":"11","author":"Schreck","year":"2019","journal-title":"Cancers"},{"key":"2023010809170179600_bib45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAP.0000000000000113","article-title":"BRAF and epithelial-mesenchymal transition: lessons from papillary thyroid carcinoma and primary cutaneous melanoma","volume":"23","author":"Mitchell","year":"2016","journal-title":"Advances in Anatomic Pathology"},{"key":"2023010809170179600_bib46","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2023010809170179600_bib47","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet: Oncology"},{"key":"2023010809170179600_bib48","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"2023010809170179600_bib49","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1158\/2159-8290.CD-19-1265","article-title":"Pan-cancer efficacy of vemurafenib in BRAF (V600)-mutant non-melanoma cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discovery"},{"key":"2023010809170179600_bib50","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2023010809170179600_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-017-0684-x","article-title":"PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation","volume":"16","author":"Tutuka","year":"2017","journal-title":"Molecular Cancer"},{"key":"2023010809170179600_bib52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","article-title":"RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling","volume":"25","author":"Yao","year":"2019","journal-title":"Nature Medicine"},{"key":"2023010809170179600_bib53","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"PNAS"},{"key":"2023010809170179600_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","article-title":"BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition","volume":"28","author":"Yao","year":"2015","journal-title":"Cancer Cell"},{"key":"2023010809170179600_bib55","doi-asserted-by":"crossref","first-page":"573.e7","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Reports"},{"key":"2023010809170179600_bib56","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0911353","article-title":"Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma","volume":"365","author":"Tantisira","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"2023010809170179600_bib57","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.2010111147","article-title":"Glcci1 deficiency leads to proteinuria","volume":"22","author":"Nishibori","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"2023010809170179600_bib58","first-page":"967","article-title":"Transcriptional control of steroid-regulated apoptosis in murine thymoma cells","volume":"10","author":"Chapman","year":"1996","journal-title":"Molecular Endocrinology"},{"key":"2023010809170179600_bib59","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1096\/fj.201800344RR","article-title":"GLCCI1 is a novel protector against glucocorticoid-induced apoptosis in T cells","volume":"33","author":"Kiuchi","year":"2019","journal-title":"FASEB Journal"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/1\/EJE-21-0797.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/1\/185\/48516339\/eje-21-0797.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/187\/1\/185\/48516339\/eje-21-0797.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:17:08Z","timestamp":1676391428000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/1\/185\/6972139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eje-21-0797","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7]]},"published":{"date-parts":[[2022,6,7]]}}}